Introduction:
Leading Pharma company delivered strong Q3 results, posting a 24.5% YoY rise in net profit. Revenue grew 9.4% annually, though it declined sequentially. Total income followed a similar trend, highlighting steady annual growth despite a quarterly dip in performance.
Also Read: PSU stock jumps after company to acquire 100% stake in Ayana Renewable Power
Share price movement of Ipca Laboratories:
On February 13, 2025, IPCA Laboratories Ltd opened at ₹1,434.95, up 1.02% from its previous close of ₹1,420.40. The stock reached a high of ₹1,525.15 (7.37%) and a low of ₹1,413.15. By 2:55 PM, it traded at ₹1,499.05, rising 5.54%, with a market cap of ₹38,018.14 crore.
Ipca Laboratories Reports 24.5% YoY Profit:
Ipca Laboratories Limited reported a 24.5% YoY increase in net profit for Q3 FY25, reaching ₹277.33 crore compared to ₹222.65 crore in the same period last year. On a QoQ basis, net profit saw a 13% rise, up from ₹245.44 crore in Q2 FY25, reflecting improved operational efficiency and profitability.
Revenue from operations grew 9.4% YoY, reaching ₹2,245.37 crore in Q3 FY25, compared to ₹2,052.85 crore in Q3 FY24. However, on a QoQ basis, revenue declined 4.6%, down from ₹2,354.90 crore in Q2 FY25, indicating a slight slowdown in quarterly sales momentum.
Total income for Q3 FY25 stood at ₹2,265.48 crore, marking a 9.2% YoY increase from ₹2,075.30 crore in Q3 FY24. However, on a QoQ basis, it fell 4.9%, down from ₹2,381.16 crore in the previous quarter, mirroring the revenue trend.
Stock performance of Ipca Laboratories for Period of 1 week, 6 months and 1 year:
Ipca Laboratories Limited’s stock declined 6.28% over the past week, reflecting short-term volatility. However, it gained 6.12% in the last six months, showing steady growth. Over the past year, it delivered a strong 23% return, highlighting long-term investor confidence.
Shareholding pattern of Ipca Laboratories:
| Dec 2024 | Sep 2024 | Jun 2024 | |
| Promoter | 44.70% | 46.30% | 46.30% |
| FII | 11.10% | 10.80% | 10.90% |
| DII | 35.70% | 34.20% | 33.80% |
| Public | 8.50% | 8.60% | 9.10% |
About Ipca Laboratories:
Ipca Laboratories Ltd (NSE: IPCALAB) is a fully integrated pharmaceutical company manufacturing over 350 formulations and 80 APIs across therapeutic segments. Among India’s top 20 pharma firms, it exports 79% of its API business to over 100 countries, ensuring supply chain reliability.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
Introduction:
Leading Pharma company delivered strong Q3 results, posting a 24.5% YoY rise in net profit. Revenue grew 9.4% annually, though it declined sequentially. Total income followed a similar trend, highlighting steady annual growth despite a quarterly dip in performance.
Also Read: PSU stock jumps after company to acquire 100% stake in Ayana Renewable Power
Share price movement of Ipca Laboratories:
On February 13, 2025, IPCA Laboratories Ltd opened at ₹1,434.95, up 1.02% from its previous close of ₹1,420.40. The stock reached a high of ₹1,525.15 (7.37%) and a low of ₹1,413.15. By 2:55 PM, it traded at ₹1,499.05, rising 5.54%, with a market cap of ₹38,018.14 crore.
Ipca Laboratories Reports 24.5% YoY Profit:
Ipca Laboratories Limited reported a 24.5% YoY increase in net profit for Q3 FY25, reaching ₹277.33 crore compared to ₹222.65 crore in the same period last year. On a QoQ basis, net profit saw a 13% rise, up from ₹245.44 crore in Q2 FY25, reflecting improved operational efficiency and profitability.
Revenue from operations grew 9.4% YoY, reaching ₹2,245.37 crore in Q3 FY25, compared to ₹2,052.85 crore in Q3 FY24. However, on a QoQ basis, revenue declined 4.6%, down from ₹2,354.90 crore in Q2 FY25, indicating a slight slowdown in quarterly sales momentum.
Total income for Q3 FY25 stood at ₹2,265.48 crore, marking a 9.2% YoY increase from ₹2,075.30 crore in Q3 FY24. However, on a QoQ basis, it fell 4.9%, down from ₹2,381.16 crore in the previous quarter, mirroring the revenue trend.
Stock performance of Ipca Laboratories for Period of 1 week, 6 months and 1 year:
Ipca Laboratories Limited’s stock declined 6.28% over the past week, reflecting short-term volatility. However, it gained 6.12% in the last six months, showing steady growth. Over the past year, it delivered a strong 23% return, highlighting long-term investor confidence.
Shareholding pattern of Ipca Laboratories:
| Dec 2024 | Sep 2024 | Jun 2024 | |
| Promoter | 44.70% | 46.30% | 46.30% |
| FII | 11.10% | 10.80% | 10.90% |
| DII | 35.70% | 34.20% | 33.80% |
| Public | 8.50% | 8.60% | 9.10% |
About Ipca Laboratories:
Ipca Laboratories Ltd (NSE: IPCALAB) is a fully integrated pharmaceutical company manufacturing over 350 formulations and 80 APIs across therapeutic segments. Among India’s top 20 pharma firms, it exports 79% of its API business to over 100 countries, ensuring supply chain reliability.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
